
CLDI
Calidi Biotherapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8151
Open
0.7729
VWAP
0.78
Vol
2.36M
Mkt Cap
26.65M
Low
0.748
Amount
1.85M
EV/EBITDA(TTM)
--
Total Shares
64.19M
EV
17.24M
EV/OCF(TTM)
--
P/S(TTM)
--
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Show More
Valuation Metrics
The current forward P/E ratio for Calidi Biotherapeutics Inc (CLDI.A) is -1.27, compared to its 5-year average forward P/E of -1.41. For a more detailed relative valuation and DCF analysis to assess Calidi Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.41
Current PE
-1.27
Overvalued PE
0.82
Undervalued PE
-3.63
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-25.03%
-5.06M
Operating Profit
FY2025Q1
YoY :
-29.94%
-5.06M
Net Income after Tax
FY2025Q1
YoY :
-91.13%
-0.18
EPS - Diluted
FY2025Q1
YoY :
+86.08%
-7.14M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
16.2K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
16.2K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CLDI News & Events
Events Timeline
2025-06-02 (ET)
2025-06-02
08:07:51
Calidi presentson CLD-401 at ASCO Annual Meeting

2025-04-28 (ET)
2025-04-28
08:13:49
Calidi selects IL15 superagonist as first payload to be delivered into tumors

2025-04-23 (ET)
2025-04-23
08:07:51
Calidi appoints Eric Poma as CEO, director

Sign Up For More Events
Sign Up For More Events
News
2.0
07-10TipRanks3 Penny Stocks to Watch Now, 7/10/25
9.0
07-10NewsfilterCancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
4.5
07-09BenzingaCrude Oil Moves Higher; RxSight Shares Plunge
Sign Up For More News
People Also Watch

SIF
SIFCO Industries Inc
5.060
USD
+1.00%

SIDU
Sidus Space Inc
2.040
USD
+3.03%

KUKE
Kuke Music Holding Ltd
2.620
USD
-0.38%

EPOW
Sunrise New Energy Co Ltd
0.915
USD
+0.22%

SYNX
Silynxcom Ltd
1.910
USD
-1.55%

TOMZ
TOMI Environmental Solutions Inc
1.000
USD
+2.04%

EQ
Equillium Inc
0.367
USD
-10.92%

VSEE
Vsee Health Inc
1.360
USD
-6.21%

SPCB
Supercom Ltd
9.360
USD
-1.99%

TOON
Kartoon Studios Inc
0.762
USD
-1.30%
FAQ

What is Calidi Biotherapeutics Inc (CLDI) stock price today?
The current price of CLDI is 0.7719 USD — it has increased 4.46 % in the last trading day.

What is Calidi Biotherapeutics Inc (CLDI)'s business?

What is the price predicton of CLDI Stock?

What is Calidi Biotherapeutics Inc (CLDI)'s revenue for the last quarter?

What is Calidi Biotherapeutics Inc (CLDI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Calidi Biotherapeutics Inc (CLDI)'s fundamentals?

How many employees does Calidi Biotherapeutics Inc (CLDI). have?
